Appendix D

Biographical Sketches of Committee Members

Paul A. Volberding, M.D. (Chair), is a professor emeritus at the University of California, San Francisco (UCSF), School of Medicine; former codirector and principal investigator of the UCSF-Gladstone Center for AIDS Research; and director of the UCSF AIDS Research Institute. Trained in medical oncology, he became involved in the early AIDS epidemic in San Francisco. He has worked in clinical trials in HIV-related malignancies but primarily in the development of antiretroviral therapy. He is a member of the National Academy of Medicine. He currently serves on the Standing Committee of Medical and Vocational Experts for the Social Security Administration’s Disability Programs of the National Academies of Sciences, Engineering, and Medicine and has chaired numerous National Academies committees, including, most recently, the Committee on Functional Assessment for Adults with Disabilities.

Jason R. Fangusaro, M.D., is director of developmental therapeutics and medical director of the Clinical Research Office at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta. He is also an associate professor of pediatrics at the Emory University School of Medicine and holds the Carter S. Martin endowed chair. As a clinical member of the pediatric neuro-oncology team, he specializes in treating children with central nervous system (CNS) malignancies, including brain and spinal cord tumors. At the Emory Winship Cancer Institute, he is a member of the Children’s Oncology Group (COG) Brain Tumor Steering Committee and serves as the vice chair of the Pediatric Brain Tumor Consortium (PBTC). He is a member of the International CNS Germ Cell Tumor Consensus

Panel and the International Low-Grade Glioma Consensus Panel. He is the principal investigator on numerous multi-institutional large studies through the COG, the PBTC, and other focused consortia.

Julia Glade Bender, M.D., is vice chair for clinical research at Memorial Sloan Kettering Cancer Center. She is a pediatric oncologist, specializing in the treatment of solid tumors of the bone and soft tissues, including osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, germ cell tumors, and other rare tumors. She is a leader in developing clinical trials and treatments for children with cancer that does not respond to standard treatment. As an ad hoc member, she serves as a consultant to the Pediatric Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration.

Andrea Hayes-Jordan, M.D., is chief of the Division of Pediatric Surgery at the University of North Carolina School of Medicine and surgeon-in-chief at the North Carolina Children’s Hospital. She has a clinical background in pediatric surgery and pioneered cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in pediatric patients. Her research focuses on the study of rare sarcomas in addition to the conduct of clinical trials establishing the proper dosage of chemotherapy for children receiving hyperthermic intraperitoneal chemotherapy. She also has a molecular biology laboratory studying a rare sarcoma. She served as chair of the Cancer Committee of the American Pediatric Surgery Association and participated in the executive committee of the Children’s Oncology Group sarcoma committee, as well as the National Cancer Advisory Board.

Brandon Hayes-Lattin, M.D., is a professor of medicine and medical director in the Division of Hematology and Medical Oncology at Oregon Health & Science University (OHSU) and medical director of the OHSU Knight Cancer Institute’s Adolescent and Young Adult (AYA) Oncology Program. His clinical background is in the management of hematologic malignancies and the use of hematopoietic stem cell transplantation. He has served as the senior medical advisor to the LIVESTRONG Foundation, the chief medical officer for Critical Mass: The Young Adult Cancer Alliance, and the inaugural chair of the AYA Committee for SWOG. He also participated on the expert advisory panel to the Children’s Oncology Group AYA Committee and was a member of the Federal Advisory Committee on Breast Cancer in Young Women of the Centers for Disease Control and Prevention.

Tara Henderson, M.D., M.P.H., is a professor in the Department of Pediatrics and interim section chief of pediatric hematology, oncology, and stem cell transplantation at UChicago Medicine at the University of Chicago, where she is also the director of the Childhood, Adolescent, and Young

Adult Cancer Survivor Center; director of cancer survivorship; and coleader for the Cancer Prevention and Control Program for the university’s Comprehensive Cancer Center. She is a pediatric oncologist with a particular interest in the care of childhood, adolescent, and young adult survivors of cancer. Her research focuses on the outcomes of survivors of childhood cancer and the development of and screening for subsequent cancers in these patients. She is principal investigator in the Childhood Cancer Survivor Study and is on the steering committees for Late Effects/Outcomes and Hodgkin Lymphoma in the Children’s Oncology Group (COG). She holds the designated pediatric oncology seat on the board of directors of the American Society of Clinical Oncology for the 2020–2024 term. She is a member of the Cancer Prevention Steering Committee of the National Cancer Institute. Dr. Henderson has received research funding from Seattle Genetics to help support a research assistant for a study embedded in a COG trial, which is now closed.

Pamela S. Hinds, R.N., Ph.D., FAAN, is the executive director of the Department of Nursing Science, Professional Practice & Quality; holds the William and Joanne Conway endowed chair in nursing research; and is the research integrity officer at Children’s National Health System. She is also a professor of pediatrics at the School of Medicine and Health Sciences at The George Washington University and an adjunct professor at the School of Nursing at the University of Pennsylvania, the School of Nursing at The Johns Hopkins University, and the College of Nursing at the University of Maryland. Her research focuses on the pediatric cancer experience, quality of life, fatigue, and altered sleep during the treatment of pediatric cancers, and on end-of-life communication and decision making. She was the inaugural chair of the nurse scholars and the inaugural codirector for the Patient-Reported Outcomes Resource Center for the Children’s Oncology Group.

Barbara L. Jones, Ph.D., is a university distinguished teaching professor and the Josleen and Frances Lockhart Memorial Professor of Direct Social Work Practice at the Steve Hicks School of Social Work at the University of Texas at Austin. She is also the school’s associate dean for health affairs and codirector of the Institute for Collaborative Health Research and Practice. At the university’s Dell Medical School, she has appointments as chair of the Social Work Department; associate director of social sciences and community-based research at the LIVESTRONG Cancer Institutes; and professor of oncology, population health, and psychiatry and behavioral sciences. Her research focuses on improving care for children, adolescents, and young adults with cancer and their families. Her current research focuses on palliative care, pediatric oncology social work interventions, and adolescent and young adult survivors.

Jennifer I. Koop, Ph.D., is an associate professor of neurology at the Medical College of Wisconsin. She is a pediatric neuropsychologist specializing in the evaluation and treatment of children with neurological, behavioral, and developmental disorders, with a particular focus on the preschool and early childhood years. Her current research investigates the effects of early neurological injury on the development of neuropsychological functions and cognitive outcomes associated with pediatric epilepsy surgery and treatment for pediatric brain tumors. She previously served on the Committee on Psychological Testing, Including Symptom Validity Testing, for Social Security Administration Disability Determinations of the National Academies of Sciences, Engineering, and Medicine.

Valerae O. Lewis, M.D., is the John Murray endowed professor and chair of the Department of Orthopaedic Oncology at the MD Anderson Cancer Center of The University of Texas in Houston, where she is also the associate director of the Department of Thoracic/Orthopaedic Center and associate director of the Sarcoma Center. She is a leader in the field of orthopaedic oncology with particular expertise in limb salvage and pelvic sarcoma surgery in adult and pediatric patients. She started the Multidisciplinary Pelvic Sarcoma Program at MD Anderson Cancer Center, which not only addresses the clinical needs of this unique group of patients but also works to improve both the clinical and functional outcomes of patients with pelvic sarcoma. Her research interest lies in the investigation and development of targeted therapy for the treatment of osteosarcoma.

Scott L. Pomeroy, M.D., Ph.D., is neurologist-in-chief and chair of the Department of Neurology at Boston Children’s Hospital and the Bronson Crothers Professor of Neurology at Harvard Medical School. His research uses molecular biology to understand neurodevelopmental origins and molecular mechanisms of childhood brain tumors, which contributed to the molecular classification of medulloblastomas that has been adopted by the World Health Organization. He has developed a genetic method of determining which patients with medulloblastoma are most likely to benefit from therapy. He is a member of the National Academy of Medicine.

David W. Pruitt, M.D., is medical director of the Inpatient Pediatric Rehabilitation Unit at Cincinnati Children’s Hospital Medical Center, where he also serves as program director of the Cancer Rehabilitation Specialty Program and director of the Pediatric Rehabilitation Medicine Fellowship. He is also a professor in the Department of Pediatrics and the Department of Neurology and Rehabilitation Medicine at the University of Cincinnati.

His clinical interests include inpatient pediatric rehabilitation, pediatric cancer rehabilitation, and pediatric neuro-oncology. His research focuses on the functional outcomes of children with brain tumors.

Leslie L. Robison, Ph.D., is chair of the Department of Epidemiology and Cancer Control, associate director of population sciences, and coleader of the Cancer Control and Survivorship Program at the Comprehensive Cancer Center at St. Jude Children’s Research Hospital. As a pediatric epidemiologist, he has had a career-long focus of etiologic and clinical research on pediatric populations, particularly childhood malignancies. He has conducted large national epidemiologic studies of childhood cancer and was the founding and long-time principal investigator of the Childhood Cancer Survivor Study, a multi-institutional consortium evaluating a cohort of more than 40,000 5-year survivors of childhood cancer. Currently he is a co–principal investigator of the St. Jude Lifetime Cohort Study, a clinical cohort of more than 8,000 survivors of childhood cancer treated at St. Jude.

Nancy J. Tarbell, M.D., is the C.C. Wang Professor of Radiation Oncology at Massachusetts General Hospital (MGH) and Harvard Medical School, where she recently served as dean for academic and clinical affairs. Previously, she led pediatric radiation oncology at Boston Children’s Hospital and MGH. She is an internationally recognized expert in pediatric oncology, particularly pediatric brain tumors, and she serves on the Brain Tumor Committee of the Children’s Oncology Group. She is a member of the National Academy of Medicine.

Emily S. Tonorezos, M.D., M.P.H., is director of the Office of Cancer Survivorship at the National Cancer Institute. She was previously director of the Adult Long-Term Follow-Up Program and associate member in the Department of Medicine at Memorial Sloan Kettering Cancer Center, and associate professor in the Department of Medicine at Weill Cornell Medical College. Her research focuses on cardiometabolic consequences of cancer therapy and care coordination for this population. She serves on the Guideline Advisory Group and the Clinical Guideline Committee for the American Society of Clinical Oncology and the Metabolic Syndrome Guideline Committee for the Children’s Oncology Group, and she is coleader of the International Guideline Harmonization Group for the metabolic syndrome.

Brigitte Widemann, M.D., is a senior investigator and head of the Pharmacology and Experimental Therapeutics Section at the National Cancer Institute (NCI). She serves as chief of NCI’s Pediatric Oncology Branch and clinical deputy director of the Center for Cancer Research. Her research

focuses on the development of early clinical trials for children and young adults with refractory cancers and genetic tumor predisposition syndrome, such as neurofibromatosis and multiple endocrine neoplasia. She serves as the principal investigator of the Phase I Consortium of the Children’s Oncology Group and of the Neurofibromatosis Consortium sponsored by the U.S. Department of Defense.